VertiGraft ACIS VG2 launhes.
NON PROFIT
1 min.Read

LifeNet Health and DePuy Synthes Launch VertiGraft ACIS VG2: Uniquely Engineered

LifeNet Health and DePuy Synthes have launched VertiGraft ACIS VG2, the first allograft interbody spacer specifically designed for DePuy Synthes’s ACIS instrumentation.

Comprised of a cancellous core and cortical endplates, VertiGraft ACIS VG2 is uniquely engineered to provide mechanical strength, reduce migration, and facilitate early vascularization and bone remodeling.1 It is the latest generation of the VertiGraft portfolio of allograft implants, which have a proven record of clinical effectiveness. A prospective study found 100% fusion rates after 12 months in 74 ACDF patients while facilitating bone growth and remodeling.2

“VertiGraft ACIS VG2 brings together the latest in structural allograft technology with state-of-the-art spinal instrumentation,” said Heather Pierce, General Manager of Global Spine and General Orthopedics at LifeNet Health. “The result is greater efficiency and flexibility for clinicians and effective healing for patients.”

The VertiGraft ACIS VG2 allograft is available in multiple footprints, in both parallel and lordotic configurations to optimize fit, fill, and saggital balance restoration. The cortical endplates provide the necessary strength to support the load of the cervical spine, and the cancellous center allows for early bone and vascular in–growth.1,3 In addition, the chamfered profile is designed for easy insertion. It is processed with LifeNet Health’s Allowash XG® and Preservon® technologies, providing the assurance of medical device-grade sterility with the convenience of room-temperature storage.

Designed and processed by LifeNet Health, VertiGraft ACIS VG2 is available exclusively through DePuy Synthes.

References

1. Fox B, Gopez A, Sukovich W, and Kerner M. Anterior Cervical Spine Fusion Rates Using a Frozen Laminated Composite Allograft and Plating The Internet Journal of Spine Surgery. 2005; 2(1).
2. Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cervical Fusion. Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.
3. Salter R B. Textbook of Disorders and Injuries of the Musculoskeletal System. 1st ed. Baltimore: Williams & Wilkins; 1970.

SourceLifeNet Health

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330